The merger with Magle Group was approved by the general meeting in July. Amniotics plans for the merger to be completed by 3 October this year. In anticipation of this, the company applied for delisting from First North in August, with a proposed last day of trading on 27 September.

Amniotics reported sales of SEK2.45m in in H1. Operating costs have decreased considerably since H1 2023 and amounted to SEK-11m before depreciations (SEK-17m in H1 2023). The result after taxes was SEK-8m. Considering the cash position was SEK0, the company can clearly not continue as a stand-alone entity.

New shares in Magle Group will be issued to Amniotics' shareholders with an exchange ratio of 6,800:1. This means 402 000 new Magle Group shares will be issued. With a Magle share price of SEK38 (rounded), this amounts to a consideration of SEK15m. This amounts to an Amniotics share price of SEK0.0056 (rounded). We expect the Amniotics' share price to roughly follow that of Magle, likely with some discrepancy due to variations in share liquidity.